Nkarta Inc
NKTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$230.38M
Close$
$-0.50
115.4% downside
Current Fair Value
115.4% downsideOvervalued by 115.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $230.38 Million |
|---|---|
| Enterprise Value | $278.02 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.41 |
| Beta | 0.9 |
| Outstanding Shares | 74,257,973 |
Return
| Return on Equity | -34.96% |
|---|---|
| Return on Assets | -26.86% |
| Return on Invested Capital | -31.29% |
Valuation & Multiples
| P/E Ratio | -2.4 |
|---|---|
| PEG | 18.51 |
| Price to Sales | - |
| Price to Book Ratio | 1.07 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.51 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5379▲ 53.79% |
|---|---|
| Total Calls | 68,600▲ Infinity% |
| Total Puts | 36,900▼ 55.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 77.92%▲ 2.62% |
|---|---|
| Total Invested | $121.64M▲ 17.92% |
| Investors Holding | 130▲ 9.00% |
ESG Score
No data
About Nkarta Inc
95 employeesNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell en...